Tumor sequencing has never been more accessible. Sequencing costs have dropped, throughput has increased, and most oncology labs can generate millions of reads from a single experiment. Yet clinically relevant mutations are still being missed not because of sequencing failure, but because detecting low-frequency somatic variants is a fundamentally different problem from generating high-quality data.

The gap between raw sequencing reads and actionable results lives in the analysis. Specifically, in whether a variant calling pipeline is built to handle the biological complexity of tumors rather than the cleaner statistical patterns typically seen in germline sequencing.

The Analytical Hurdle of Detecting Somatic Mutations in Cancer

Somatic variants in cancer do not behave like inherited germline variants. In germline genetics, heterozygous variants typically appear near 50% allele frequency, while homozygous variants approach 100%. Tumor biology is far less predictable.

A driver mutation present in a subclone may appear at 5% variant allele frequency (VAF) or even lower. Healthy stromal tissue, infiltrating immune cells, variable tumor purity, and clonal heterogeneity all dilute the signal. In a heterogeneous tumor sample, the mutation that matters most an emerging resistance mutation or a rare subclonal driver may be represented by only a small fraction of sequencing reads.

At these frequencies, distinguishing a genuine variant from PCR artifacts, mapping errors, sequencing noise, or strand bias becomes significantly more challenging. Variant callers designed primarily for germline analysis are not optimized for this problem. Applying them directly to tumor data can increase false negatives at precisely the variants that carry the greatest biological and clinical significance.

To recover these signals reliably, variant calling workflows must use statistical models capable of separating true low-frequency mutations from background technical noise while maintaining confidence in the final call set.

Sensitivity Alone Isn’t the Answer

The natural response to missing variants is often to lower filtering thresholds and retain more calls. However, permissive filtering introduces a different challenge: false positives that increase review burden, complicate interpretation, and reduce confidence in downstream analyses.

Modern somatic callers such as Mutect2 and Strelka2 address this problem through likelihood-based models that evaluate multiple signals simultaneously, including read depth, base quality, mapping quality, strand orientation, and allele frequency. Rather than relying on a single threshold, these tools assess the probability that a variant represents a true biological event.

Matched tumor-normal analysis adds another layer of confidence by using the normal sample as a reference to distinguish inherited germline variants from tumor-specific mutations. Clinical samples also present additional challenges, including FFPE-associated artifacts and oxidative damage signatures that require dedicated handling strategies beyond those available in generic analysis pipelines.

Achieving both sensitivity and specificity requires a workflow designed specifically for tumor biology rather than one adapted from a different analytical context.

Reproducibility Is a Clinical Concern, Not Just a Computational One

A variant call that appears in one analysis run but not another is difficult to trust. In oncology, inconsistency affects far more than computational workflows. It influences which mutations are reported, which patients may qualify for clinical trials, and which biomarkers progress through validation studies.

Many reproducibility issues in somatic variant calling originate from the same underlying factors: inconsistent software versions, changing reference genome builds, variable filtering parameters, and differences in execution environments. As studies scale across larger cohorts, these inconsistencies can compound and create the appearance of biological variation where analytical variation may be contributing to the observed differences.

Standardized workflows help reduce this risk. Locked software environments, documented filtering strategies, version-controlled reference resources, and consistent annotation against databases such as COSMIC and ClinVar improve confidence that results can be reproduced across projects, operators, and time.

What a Production-Ready Somatic Calling Workflow Actually Requires

Not every pipeline marketed for cancer genomics is built to support the demands of translational research and biomarker discovery. Evaluating a somatic variant calling workflow requires looking beyond processing speed or automation claims.

The most important questions are practical:

• Can the workflow reliably detect variants below 5% VAF without substantially increasing false-positive rates?
• Does it support matched tumor-normal analysis or operate without a germline reference?
• How are FFPE artifacts, duplicate reads, and mapping challenges in repetitive genomic regions handled?
• Are software versions, reference genomes, and annotation resources standardized and controlled?
• Does variant annotation integrate with clinically and biologically relevant resources such as COSMIC and ClinVar?

These are not advanced or optional considerations. They represent the baseline requirements for generating variant calls that can support downstream biological interpretation with confidence.

The Real Cost of Getting This Wrong

Missed low-frequency variants are not a theoretical concern. Subclonal resistance mutations, early clonal evolution signals, and rare driver events in heterogeneous tumors can all remain hidden when analysis workflows are not optimized for low-VAF detection.

In many cases, the sequencing data already contains the answer. Whether that answer is recovered depends largely on the design and rigor of the analysis pipeline.

At GenomeBeans, our cloud-based NGS workflows are built around this challenge specifically. From raw FASTQ files through annotated variant reports, somatic variant calling workflows are standardized to improve reproducibility while maintaining sensitivity to clinically relevant signals. The objective is not to replace scientific judgment, but to ensure that the variants most deserving of scrutiny are consistently identified and made available for interpretation.

See How Easy It Is to Review Your Data

GenomeBeans provides a cloud-based platform for standardized somatic variant analysis, helping researchers move from raw sequencing data to annotated results through reproducible workflows.

Explore a sample analysis output to see how variant calls, annotations, and quality metrics are presented:

View Sample Analysis Report

Whether you’re evaluating low-frequency variants, reviewing tumor-normal comparisons, or assessing biomarker candidates, having a consistent analysis framework can make interpretation more efficient and reproducible.